Compare NMIH & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMIH | TWST |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2013 | 2018 |
| Metric | NMIH | TWST |
|---|---|---|
| Price | $41.05 | $49.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $42.60 | ★ $50.22 |
| AVG Volume (30 Days) | 532.2K | ★ 1.5M |
| Earning Date | 02-10-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.56 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $692,208,000.00 | $391,557,000.00 |
| Revenue This Year | N/A | $16.77 |
| Revenue Next Year | $4.79 | $15.06 |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | 8.86 | ★ 18.59 |
| 52 Week Low | $31.90 | $23.30 |
| 52 Week High | $43.20 | $54.74 |
| Indicator | NMIH | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 70.96 |
| Support Level | $37.83 | $44.91 |
| Resistance Level | $38.70 | $48.73 |
| Average True Range (ATR) | 0.95 | 2.57 |
| MACD | 0.38 | 0.32 |
| Stochastic Oscillator | 94.69 | 91.89 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.